skip to main content

GLP-1 RA Weight Benefit CKD — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

ModerateDiabetic Kidney DiseaseGLP-1 RA Weight Benefit CKDESENeph

A 28-year-old woman with type 2 diabetes (BMI 38) and CKD G3aA2 (eGFR 50 mL/min/1.73m2, uACR 15 mg/mmol) is on Ramipril and Metformin. HbA1c is 68 mmol/mol. Her clinician wants to add a GLP-1 RA. According to KDIGO 2024, which additional benefit makes GLP-1 RA particularly appropriate?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Weight management in addition to glycaemic and cardiovascular benefits

KDIGO 2024 CKD guideline and holistic approach figure include weight management as a key component of CKD care. GLP-1 RAs provide weight reduction (typically 5-15% depending on agent), glycaemic control, and cardiovascular risk reduction. In a patient with BMI 38, the weight loss benefit is particularly valuable. The FLOW trial (Semaglutide) also showed kidney-protective effects. KDIGO recommends prioritising GLP-1 RAs with documented cardiovascular benefits.

Reference: KDIGO 2024 – CKD Guideline; FLOW Trial 2024